Lates News

According to the report from Citic Securities, the first therapeutic HPV vaccine PRGN-2012 has been approved for market launch, filling the treatment gap in the field of Recurrent Respiratory Papillomatosis (RRP) and also boosting the prosperity of the innovative therapeutic vaccine industry. Overseas therapeutic vaccine pipelines are progressing rapidly with various technological platforms flourishing. It is expected that there will be a series of important data releases in the industry in the near future and within the next 1-2 years, leading to a period of intensive catalysis. Meanwhile, with the empowerment of AI, the efficiency of antigen design will be further improved, and the vaccine research and production are expected to accelerate. It is recommended to pay attention to related targets in the layout of therapeutic vaccines.